Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-41165
Titel: Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
VerfasserIn: Böhm, Michael
Butler, Javed
Mahfoud, Felix
Filippatos, Gerasimos
Ferreira, João Pedro
Pocock, Stuart J.
Slawik, Jonathan
Brueckmann, Martina
Linetzky, Bruno
Schüler, Elke
Wanner, Christoph
Zannad, Faiez
Packer, Milton
Anker, Stefan D.
Sprache: Englisch
Titel: European Journal of Heart Failure
Bandnummer: 24
Heft: 10
Seiten: 1883-1891
Verlag/Plattform: Wiley
Erscheinungsjahr: 2022
Freie Schlagwörter: Empagliflozin
Heart failure
Cardiovascular outcomes
Resting heart rate
Atrial fibrillation
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR and empagliflozin effects in EMPEROR-Preserved was evaluated. We grouped patients (n = 5988) according to their baseline RHR (<70 bpm [n = 2650], 70–75 bpm [n = 967], >75 bpm [n = 1736]) and explored the influence of RHR on CVD or HHF (primary outcome) and its components in sinus rhythm or atrial fibrillation/flutter (AF) and adverse events. We studied the efficacy of empagliflozin across the RHR spectrum. Compared to placebo, empagliflozin did not change heart rate over time. The primary outcome (p for trend = 0.0004) and its components CVD (p trend = 0.0002), first HHF (p for trend = 0.0099) and all-cause death (p <  0.0001) increased with RHR only in sinus rhythm but not AF. The risk increase with RHR was similar in patients with heart failure and mildly reduced ejection fraction (left ventricular ejection fraction [LVEF] 40–49%) and HFpEF (LVEF ≥50%). Baseline RHR had no influence on the effect of empagliflozin on the primary outcomes (p for trend = 0.20), first HHF (p for trend = 0.49). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the RHR groups. Conclusion Resting heart rate associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events.
DOI der Erstveröffentlichung: 10.1002/ejhf.2677
URL der Erstveröffentlichung: https://doi.org/10.1002/ejhf.2677
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-411651
hdl:20.500.11880/36937
http://dx.doi.org/10.22028/D291-41165
ISSN: 1879-0844
1388-9842
Datum des Eintrags: 24-Nov-2023
Bezeichnung des in Beziehung stehenden Objekts: Supporting Information
In Beziehung stehendes Objekt: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fejhf.2677&file=ejhf2677-sup-0001-Supinfo.pdf
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Prof. Dr. Michael Böhm
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons